The approval relies on positive data from the POTOMAC Phase III trial.

ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.

Combination significantly improved disease-free survival in phase III trial ...

AstraZeneca’s IMFINZI ® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve ...

FDA approval establishes durvalumab plus BCG induction and maintenance as a new immunotherapy-based option for BCG-naïve, high-risk NMIBC following TURBT, potentially redefining the frontline ...

Male doctor explaining senior couple over laptop. Elderly man and woman are listening to medical expertise. They are sitting at desk in hospital. After the BCG shortage began, patients with non-muscle ...

ImmunityBio (NasdaqGS:IBRX) presented new clinical data on ANKTIVA in advanced non small cell lung cancer and BCG unresponsive non muscle invasive bladder cancer at the 2026 ASCO Annual Meeting. The ...

The U.S. FDA has approved Durvalumab in combination with bacillus Calmette-Guérin (BCG) for adults with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC). The approval was based ...

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...

Bacillus Calmette-Guérin (BCG) vaccine is the live attenuated vaccine form of Mycobacterium bovis used to prevent tuberculosis and other mycobacterial infections. Now, using zebrafish “avatars,” a ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...